logo-loader

Todos wins US trademark for its 3CL protease inhibitor oral antiviral drug candidate Tollovir

Published: 12:57 20 Sep 2021 EDT

Todos Medical Ltd. wins US trademark for its 3CL protease inhibitor oral antiviral drug candidate Tollovir
The company said results from the first clinical trial of Tollovir are being readied for release

Todos Medical Ltd. (OTCQB:TOMDF) revealed that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a trademark covering the company’s proprietary 3CL protease inhibitor oral antiviral drug candidate NLC-V-01, also known as Tollovir.

A notice of allowance is normally a written notification from the USPTO saying a specific mark has survived the opposition period following publication in the Official Gazette and has consequently been allowed.

In a statement, Todos Medical CEO Gerald E Commissiong said the USPTO “moved quickly” to authorize Tollovir’s trademark so that there would be a “clear regulatory and marketing distinction” with the company’s dietary supplement product Tollovid.

READ: Todos Medical says its Provista Diagnostics lab completes validation of Kogene Variant Test Kit to identify coronavirus variants

“We are pleased with the speed with which the trademark for the brand name of our coronavirus (COVID-19) 3CL protease inhibitor oral antiviral drug candidate Tollovir was issued,” said Commissiong.

“While we are pushing forward with our efforts to complete ongoing clinical studies in Israel and initiate pivotal studies in India, we are also very focused on engaging the US Food and Drug Administration to evaluate Tollovir potentially as part of the Emergency Use Authorization pathway in the US. Results from the first clinical trial of Tollovir are being readied for release.”

In 2020, a Phase 1/2 clinical study evaluating the safety and efficacy of Tollovir in hospitalized patients was completed by the diagnostic solutions company’s joint venture partner NLC Pharma Israel.

Todos and NLC Pharma are currently enrolling a Phase 2 clinical study in Israel in hospitalized patients. Pivotal Phase 2/3 clinical studies are currently being planned for both hospitalized and non-hospitalized patients.

Tollovir is the result of over 15 years of development and an investment of over $18 million to date, according to the Todos website.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

3 hours, 10 minutes ago